195 related articles for article (PubMed ID: 32552362)
1. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
[TBL] [Abstract][Full Text] [Related]
3. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
Olfson M; Amos TB; Benson C; McRae J; Marcus SC
J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
[TBL] [Abstract][Full Text] [Related]
4. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
[TBL] [Abstract][Full Text] [Related]
5. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
[TBL] [Abstract][Full Text] [Related]
6. Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care.
Liberman JN; Davis T; Pesa J; Chow W; Verbanac J; Heverly-Fitt S; Ruetsch C
J Manag Care Spec Pharm; 2020 Aug; 26(8):987-995. PubMed ID: 32715964
[TBL] [Abstract][Full Text] [Related]
7. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
8. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
Pilon D; Sheehan JJ; Szukis H; Morrison L; Zhdanava M; Lefebvre P; Joshi K
J Affect Disord; 2019 Aug; 255():50-59. PubMed ID: 31128505
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of treatment-resistant depression among veterans in the United States.
Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ
Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005
[TBL] [Abstract][Full Text] [Related]
10. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
11. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
[TBL] [Abstract][Full Text] [Related]
12. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
13. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
[No Abstract] [Full Text] [Related]
14. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression.
Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H
Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Relationship Between Depression Symptom Severity and Health Care Costs for Patients With Treatment-Resistant Depression.
Lynch FL; Dickerson JF; O'Keeffe-Rosetti M; Chow W; Pesa J
J Clin Psychiatry; 2022 Feb; 83(2):. PubMed ID: 35120286
[No Abstract] [Full Text] [Related]
16. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
[TBL] [Abstract][Full Text] [Related]
17. Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression.
Pilon D; Szukis H; Singer D; Morrison L; Sheehan JJ; Lefebvre P
Curr Med Res Opin; 2020 May; 36(5):865-874. PubMed ID: 31985319
[No Abstract] [Full Text] [Related]
18. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
19. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode.
Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C
Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559
[No Abstract] [Full Text] [Related]
20. Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.
Shah D; Allen L; Zheng W; Madhavan SS; Wei W; LeMasters TJ; Sambamoorthi U
Pharmacoeconomics; 2021 Jun; 39(6):639-651. PubMed ID: 33904144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
